Literature DB >> 26289042

Response to: 'Body mass index and the risk of rheumatoid arthritis: a systematic review and dose-response meta-analysis'--authors' reply.

Baodong Qin1, Yan Liang1, Zaixing Yang2, Renqian Zhong3.   

Abstract

Entities:  

Mesh:

Year:  2015        PMID: 26289042      PMCID: PMC4545877          DOI: 10.1186/s13075-015-0745-8

Source DB:  PubMed          Journal:  Arthritis Res Ther        ISSN: 1478-6354            Impact factor:   5.156


× No keyword cloud information.
We thank Liu and Barnabe for their valuable comments [1] on our article [2]. We think the majority of the remarks they made were reasonable and helpful for a deep understanding of the association of body mass index (BMI) and rheumatoid arthritis (RA) risk. Indeed, the three papers they mentioned discussed the role of obesity in RA development. Actually, we also identified these three papers when searching for potential papers; however, our paper is not a descriptive review, but a quantitative systematic review. We had strict inclusion criteria as described in our paper, with included studies having to fulfill the following criteria: (1) the study had a case–control or cohort design; (b) the study included risk estimates with the corresponding 95 % confidence intervals, or sufficient data for extraction or assessment; and (c) obesity, being overweight, and BMI were the exposures of interest [2]. Hemminki et al. [3] estimated standardized incidence ratio for RA in obese individuals compared with those who had not been hospitalized for obesity. This study was a cohort design and obesity was the exposure of interest, but we could not extract and calculate the risk estimates of RA development in the obese population. We therefore excluded this paper. Vessey et al. [4] reported no significant association between RA development and either weight or height. The exposure of interest was not obesity, being overweight, or BMI. Besides, no risk estimates could be obtained from this paper. For similar reasons we did not include Bartfai et al.'s paper [5]. Thus, we did not include these three papers due to insufficient data for calculation of pooled risk estimates. Although several studies gave negative results, the combined results obtained from our quantitative meta-analysis have demonstrated that an increase in BMI could contribute to a higher risk for RA development. However, the real relationship between obesity, BMI and RA risk should be conducted in a large RA cohort with adjustment for more confounding factors.
  5 in total

1.  Risk of asthma and autoimmune diseases and related conditions in patients hospitalized for obesity.

Authors:  Kari Hemminki; Xinjun Li; Jan Sundquist; Kristina Sundquist
Journal:  Ann Med       Date:  2011-02-01       Impact factor: 4.709

Review 2.  Adipose tissue as a modulator of clinical inflammation: does obesity reduce the prevalence of rheumatoid arthritis?

Authors:  Tamas Bartfai; Jill Waalen; Joel N Buxbaum
Journal:  J Rheumatol       Date:  2007-02-15       Impact factor: 4.666

3.  Oral contraceptives, cigarette smoking and other factors in relation to arthritis.

Authors:  M P Vessey; L Villard-Mackintosh; D Yeates
Journal:  Contraception       Date:  1987-05       Impact factor: 3.375

Review 4.  Body mass index and the risk of rheumatoid arthritis: a systematic review and dose-response meta-analysis.

Authors:  Baodong Qin; Min Yang; Haitao Fu; Ning Ma; Tingting Wei; Qingqin Tang; Zhide Hu; Yan Liang; Zaixing Yang; Renqian Zhong
Journal:  Arthritis Res Ther       Date:  2015-03-29       Impact factor: 5.156

5.  Response to 'Body mass index and the risk of rheumatoid arthritis: a systematic review and dose-response meta-analysis'.

Authors:  Yang Liu; Cheryl Barnabe
Journal:  Arthritis Res Ther       Date:  2015-08-19       Impact factor: 5.156

  5 in total
  1 in total

1.  MicroRNA-140-5p regulates the proliferation, apoptosis and inflammation of RA FLSs by repressing STAT3.

Authors:  Jiehua Zhu; Jianglin Wang; Jialin Huang; Wensheng Du; Yingzhong He; Hongfei Pan; Junmin Luo
Journal:  Exp Ther Med       Date:  2020-12-27       Impact factor: 2.447

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.